These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 7035306)

  • 41. FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy.
    Tan SM; Zhang Y; Wang B; Tan CY; Zammit SC; Williams SJ; Krum H; Kelly DJ
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):650-6. PubMed ID: 22612418
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression.
    Zheng M; Ye S; Zhai Z; Chen Y; Li X; Yang G; Fan A; Wang Y
    J Diabetes Complications; 2009; 23(2):124-9. PubMed ID: 18413206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The morphology of diabetic nephropathy in experimental diabetes induced by low doses of streptozotocin].
    Varshavskiĭ VA; Ponomarev AB; Bazarova AV; Karelin AA; Pankov IuA; Kondrat'ev IaIu; Keda IuM; Gorskova VA
    Arkh Patol; 1990; 52(7):43-8. PubMed ID: 2149496
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crocin attenuate Tumor Necrosis Factor-alpha (TNF-α) and interleukin-6 (IL-6) in streptozotocin-induced diabetic rat aorta.
    Samarghandian S; Azimi-Nezhad M; Farkhondeh T
    Cytokine; 2016 Dec; 88():20-28. PubMed ID: 27529541
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolonging prostacyclin production by nafazatrom or dipyridamole.
    Deckmyn H; Gresele P; Arnout J; Todisco A; Vermylen J
    Lancet; 1984 Aug; 2(8399):410-1. PubMed ID: 6147492
    [No Abstract]   [Full Text] [Related]  

  • 47. Stability of prostacyclin in plasma.
    Jørgensen KA; Stoffersen E; Dyerberg J
    Lancet; 1979 Jun; 1(8130):1352. PubMed ID: 87815
    [No Abstract]   [Full Text] [Related]  

  • 48. Release of prostacyclin into the bloodstream and its exhaustion in humans after local blood flow changes (ischemia and venous stasis).
    Serneri GG; Masotti G; Poggesi L; Galanti G
    Thromb Res; 1980 Jan 1-15; 17(1-2):197-208. PubMed ID: 6990547
    [No Abstract]   [Full Text] [Related]  

  • 49. A clinical study of nafazatrom in advanced human breast cancer.
    Jones AL; Powles TJ; Forgeson GV; Coombes RC
    Cancer Chemother Pharmacol; 1991; 27(4):326-8. PubMed ID: 1998990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostacyclin release in vivo.
    Dandona P; Mikhailidis DP; Jeremy JY
    Lancet; 1983 Apr; 1(8328):823-4. PubMed ID: 6132160
    [No Abstract]   [Full Text] [Related]  

  • 51. Increased release of vascular prostacyclin-like activity after long-term treatment of diabetic rats with Bay g 6575.
    Chamone DA; van Damme B; Carreras LO; Vermylen J
    Haemostasis; 1981; 10(6):297-303. PubMed ID: 7035306
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.